Summit Therapeutics SMMT Stock
Summit Therapeutics Price Chart
Summit Therapeutics SMMT Financial and Trading Overview
| Summit Therapeutics stock price | 18.91 USD |
| Previous Close | 1.95 USD |
| Open | 1.93 USD |
| Bid | 0 USD x 1100 |
| Ask | 0 USD x 2900 |
| Day's Range | 1.93 - 2.07 USD |
| 52 Week Range | 0.66 - 5.78 USD |
| Volume | 2.63M USD |
| Avg. Volume | 1.65M USD |
| Market Cap | 1.4B USD |
| Beta (5Y Monthly) | -1.031338 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.31 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5 USD |
SMMT Valuation Measures
| Enterprise Value | 1.22B USD |
| Trailing P/E | N/A |
| Forward P/E | -1.8518518 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 3066.7473 |
| Price/Book (mrq) | 10.471204 |
| Enterprise Value/Revenue | 2687.337 |
| Enterprise Value/EBITDA | -21.107 |
Trading Information
Summit Therapeutics Stock Price History
| Beta (5Y Monthly) | -1.031338 |
| 52-Week Change | 104.08% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 5.78 USD |
| 52 Week Low | 0.66 USD |
| 50-Day Moving Average | 1.69 USD |
| 200-Day Moving Average | 2 USD |
SMMT Share Statistics
| Avg. Volume (3 month) | 1.65M USD |
| Avg. Daily Volume (10-Days) | 1.56M USD |
| Shares Outstanding | 697.68M |
| Float | 114.58M |
| Short Ratio | 2.47 |
| % Held by Insiders | 29.61% |
| % Held by Institutions | 1.26% |
| Shares Short | 4.57M |
| Short % of Float | 3.98% |
| Short % of Shares Outstanding | 0.66% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | -12959.78% |
| Gross Margin | 100.00% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.84% |
| Return on Equity (ttm) | -606.15% |
Income Statement
| Revenue (ttm) | 455K USD |
| Revenue Per Share (ttm) | 0.002 USD |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | 705K USD |
| EBITDA | -57931000 USD |
| Net Income Avi to Common (ttm) | -599761024 USD |
| Diluted EPS (ttm) | -1.85 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 241.93M USD |
| Total Cash Per Share (mrq) | 0.35 USD |
| Total Debt (mrq) | 104.18M USD |
| Total Debt/Equity (mrq) | 78.05 USD |
| Current Ratio (mrq) | 14.219 |
| Book Value Per Share (mrq) | 0.191 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -35712000 USD |
| Levered Free Cash Flow (ttm) | -22206376 USD |
Profile of Summit Therapeutics
| Country | United States |
| State | MA |
| City | Cambridge |
| Address | 2882 Sand Hill Road, Suite 106 |
| ZIP | 94025 |
| Phone | (650) 460-8308 |
| Website | https://www.summittxinc.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 76 |
Summit Therapeutics Inc., a biopharmaceutical company, research and develops primarily oncology therapies in the United States, and the United Kingdom. The company's product pipeline includes SMT-738, a novel class of precision antibiotics for treatment which is in preclinical stage for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. for research and develop Ivonescimab (AK112) and SMT112, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis. The company was founded in 2003 and is headquartered in Cambridge, Massachusetts.
Q&A For Summit Therapeutics Stock
What is a current SMMT stock price?
Summit Therapeutics SMMT stock price today per share is 18.91 USD.
How to purchase Summit Therapeutics stock?
You can buy SMMT shares on the NasdaqGM exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Summit Therapeutics?
The stock symbol or ticker of Summit Therapeutics is SMMT.
Which industry does the Summit Therapeutics company belong to?
The Summit Therapeutics industry is Biotechnology.
How many shares does Summit Therapeutics have in circulation?
The max supply of Summit Therapeutics shares is 737.68M.
What is Summit Therapeutics Price to Earnings Ratio (PE Ratio)?
Summit Therapeutics PE Ratio is now.
What was Summit Therapeutics earnings per share over the trailing 12 months (TTM)?
Summit Therapeutics EPS is -0.31 USD over the trailing 12 months.
Which sector does the Summit Therapeutics company belong to?
The Summit Therapeutics sector is Healthcare.
Summit Therapeutics SMMT included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| NASDAQ Composite Total Return I XCMP | 20257.83 USD — |
-5.96
|
— — | 20236.33 USD — | 20672.41 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
| NASDAQ Global Market Composite NQGM | 1737.75 USD — |
-6
|
— — | 1724.84 USD — | 1770.8 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
- {{ link.label }} {{link}}